Nebenwirkungen von Psychopharmaka: Tipps für die Praxis

Abstract

Psychotropics are highly effective medications that, however, have adverse drug reactions attached to them. They are indispensable for many patients. How to cope with side effects – watchful waiting, dose reduction, change of medication, addition of an “antidote” and behavioural modifications – depends on their nature, severity and finally the patients wish. This review is meant to aid clinician’s and patient’s decisions in case of the occurrence of compromising, frequent adverse drug reactions.

Psychopharmaka sind hochwirksame, aber auch mit Nebenwirkungen behaftete Medikamente, die für viele Patienten unverzichtbar sind. Der Umgang mit Nebenwirkungen – Zuwarten, Dosisreduktion, Medikamentenwechsel, Zugabe eines „Antidots“ sowie spezielle Verhaltensmaßnahmen – hängt von ihrer Art, Schwere und dem Wunsch des Patienten ab. Dieser Beitrag soll Arzt und Patient Entscheidungshilfen bei häufigen und beeinträchtigenden Nebenwirkungen bieten.

Schlüsselwörter

Antidepressiva - Antipsychotika - Psychopharmaka - unerwünschte Arzneimittelwirkung/-reaktion

Key words

antidepressants - antipsychotics - psychotropics - adverse drug reaction

• Literatur

• 1 Fuertes JN, Mislowack A, Bennett J. et al. The physician-patient working alliance. Patient Educ Couns 2007; 66: 29-36
• 2 Vos T, Flaxman AD, Naghavi M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196
• 3 Angst F, Stassen HH, Clayton PJ. et al. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002; 68: 167-181
• 4 Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004; 66: 802-813
• 5 Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27: 2763-2774
• 6 Fikenzer K, Knoll A, Lenski D. et al. Chronische Herzinsuffizienz: Teufelskreis aus geringer Einnahmetreue von Medikamenten und kardialer Dekompensation. Dtsch Med Wochenschr 2014; 139: 2390-2394
• 7 Leucht S, Hierl S, Kissling W. et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106
• 8 Carvalho AF, Sharma MS, Brunoni AR. et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016; 85: 270-288
• 9 Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357-368
• 10 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 11. Aufl. Heidelberg: Springer; 2017
• 11 Gründer G, Benkert O. Handbuch der Psychopharmakotherapie. 2. Aufl. Heidelberg: Springer; 2012
• 12 Zaudig M, Trautmann-Sponsel RD, Joraschky P. et al. Therapielexikon Psychiatrie, Psychosomatik, Psychotherapie. Heidelberg: Springer; 2006
• 13 Dunner DL, Wohlreich MM, Mallinckrodt CH. et al. Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses. Curr Ther Res Clin Exp 2005; 66: 522-540
• 14 Kraus T, Haack M, Schuld A. et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314
• 15 Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun 2010; 11: 145-156
• 16 Zheng W, Li XB, Tang YL. et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2015; 35: 499-509
• 17 Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother 2005; 39: 748-752
• 18 Mago R, Thase ME, Rovner BW. Antidepressant-induced excessive sweating: clinical features and treatment with terazosin. Ann Clin Psychiatry 2013; 25: 186-192
• 19 Mago R. Glycopyrrolate for antidepressant-associated excessive sweating. J Clin Psychopharmacol 2013; 33: 279-280
• 20 Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich) 2013; 15: 147-153
• 21 Cartwright C, Gibson K, Read J. et al. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence 2016; 10: 1401-1407
• 22 Clayton AH, Alkis AR, Parikh NB. et al. Sexual dysfunction due to psychotropic medications. Psychiatr Clin North Am 2016; 39: 427-463
• 23 Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc 2016; 91: 1280-1286
• 24 Kennedy SH, Dickens SE, Eisfeld BS. et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999; 56: 201-208
• 25 Taylor MJ, Rudkin L, Bullemor-Day P. et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; 5
• 26 Mir A, Shivakumar K, Williamson RJ. et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008; 22: 244-253
• 27 Montalvo I, Ortega L, Lopez X. et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol 2013; 28: 46-49
• 28 Khouzam HR. Identification and management of tardive dyskinesia: A case series and literature review. Postgrad Med 2015; 127: 726-737
• 29 Bhidayasiri R, Fahn S, Weiner WJ. et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81: 463-469
• 30 Nistico R, Fratto A, Vescio B. et al. Tremor pattern differentiates drug-induced resting tremor from Parkinson disease. Parkinsonism Relat Disord 2016; 25: 100-103
• 31 Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000; 22: 73-81
• 32 Lohr JB, Eidt CA, Abdulrazzaq AA. et al. The clinical challenges of akathisia. CNS Spectr 2015; 20: 1-14